New Page 1
 

COPD-X Menu
COPD-X Menu COPD-X Home Page COPD-X Guidelines Management Tools Case Statements News & Resources COPD Institute Contact Us
COPD-X Menu

 

COPD Intitute > Management Tools > Appendices > Authors > Refs 51-100

References 51 - 100

Refs 1 - 50 Refs 51 - 100 Refs 101 - 150 Refs 151 - 200 Refs 201 - 250 Refs 251 - 291
Note: [return to text] - goes to the last page in viewed in COPD-X regardless of reference number.
 
51 Lee, T.A., et al., Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med, 2008. 149(6): p. 380-90.
52 Singh, S., Y.K. Loke, and C.D. Furberg, Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama, 2008. 300(12): p. 1439-50.
53 Barr, R.G., et al., Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax, 2006. 61(10): p. 854-62.
54 Barr, R.G., et al., Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2005(2): p. CD002876.
55 Kesten, S., et al., Pooled clinical trial analysis of tiotropium safety. Chest, 2006. 130(6): p. 1695-703.
56 Tashkin, D.P., et al., A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 2008. 359(15): p. 1543-54.
57 Appleton, S., et al., Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2006. 3: p. CD001104.
58 Molfino, N.A. and P. Zhang, A meta-analysis on the efficacy of oral theophylline in patients with stable COPD. Int J Chron Obstruct Pulmon Dis, 2006. 1(3): p. 261-6.
59 Chrystyn, H., B.A. Mulley, and M.D. Peake, Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ, 1988. 297(6662): p. 1506-10.
60 Ram, F.S., et al., Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2002(4): p. CD003902.
61 Murciano, D., et al., A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med, 1989. 320(23): p. 1521-5.
62 McKay, S.E., et al., Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax, 1993. 48(3): p. 227-32.
63 Taylor, D.R., et al., The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis, 1985. 131(5): p. 747-51.
64 Aubier, M., Pharmacotherapy of respiratory muscles. Clin Chest Med, 1988. 9(2): p. 311-24.
65 Moxham, J., Aminophylline and the respiratory muscles: an alternative view. Clin Chest Med, 1988. 9(2): p. 325-36.
66 Barnes, P.J., Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med, 2003. 167(6): p. 813-8.
67 Kobayashi, M., et al., Effect of low-dose theophylline on airway inflammation in COPD. Respirology, 2004. 9(2): p. 249-54.
68 Zhou, Y., et al., Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology, 2006. 11(5): p. 603-10.
69 MIMS Australia Pty Ltd. MIMS Online.  2008  [cited; Available from: http://www.mims.com.au/.
70 Rennard, S.I., et al., Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest, 2006. 129(1): p. 56-66.
71 Rabe, K.F., et al., Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 2005. 366(9485): p. 563-71.
72 Postma, D.S., et al., Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J, 1988. 1(1): p. 22-6.
73 Postma, D.S., et al., Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis, 1985. 67(1): p. 56-64.
74 Decramer, M., V. de Bock, and R. Dom, Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1996. 153(6 Pt 1): p. 1958-64.
75 Decramer, M., et al., Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med, 1994. 150(1): p. 11-6.  [return to text]
76 Decramer, M. and K.J. Stas, Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis, 1992. 146(3): p. 800-2.
77 Senderovitz, T., et al., Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir Med, 1999. 93(10): p. 715-8.
78 Vestbo, J., et al., Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 1999. 353(9167): p. 1819-23.
79 Miravitlles, M., et al., Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax, 2004. 59(5): p. 387-95.
80 Yang, I.A., et al., Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2007(2): p. CD002991.
81 Calverley, P.M., et al., Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007. 356(8): p. 775-89.
82 Pauwels, R.A., et al., Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med, 1999. 340(25): p. 1948-53.
83 Wouters, E.F., et al., Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax, 2005. 60(6): p. 480-7.
84 Nannini, L., et al., Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2004(3): p. CD003794.
85 Kardos, P., et al., Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2007. 175(2): p. 144-9.
86 Ernst, P., et al., Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med, 2007. 176(2): p. 162-6.
87 Wedzicha, J.A., et al., The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med, 2008. 177(1): p. 19-26.
88 Aaron, S.D., et al., Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med, 2007. 146(8): p. 545-55.
89 NHS Centre for Reviews and Dissemination, Inhaler devices for the management of asthma and COPD. Effective Healthcare: Bulletin on the Effectiveness of Health Service Interventions for Decision Makers, 2003. 8(1): p. 1-12.
90 Pitta, F., et al., Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2005. 171(9): p. 972-7.
91 Garcia-Aymerich, J., et al., Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax, 2006. 61(9): p. 772-8.
92 Nici, L., et al., American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med, 2006. 173(12): p. 1390-413.
93 Ries, A.L., et al., Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest, 2007. 131(5 Suppl): p. 4S-42S.
94 Lacasse, Y., et al., Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2006(4): p. CD003793.
95 Chavannes, N., et al., Effects of physical activity in mild to moderate COPD: a systematic review. Br J Gen Pract, 2002. 52(480): p. 574-8.
96 Lotters, F., et al., Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J, 2002. 20(3): p. 570-6.
97 Geddes, E.L., et al., Inspiratory muscle training in adults with chronic obstructive pulmonary disease: a systematic review. Respir Med, 2005. 99(11): p. 1440-58.
98 Crowe, J., et al., Inspiratory muscle training compared with other rehabilitation interventions in adults with chronic obstructive pulmonary disease: a systematic literature review and meta-analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005. 2(3): p. 319-29.
99 Brooks, D., et al., The effect of postrehabilitation programmes among individuals with chronic obstructive pulmonary disease. Eur Respir J, 2002. 20(1): p. 20-9.
100 Blackstock, F. and K. Webster, Disease-specific health education for COPD: a systematic review of changes in health outcomes. Health Educ Res, 2007. 22(5): p. 703-17.  [return to text]

 

Next Page Previous Page